Ocal Yigit, Kurum Baris, Karahan Siyami, Tezcaner Aysen, Ozen Seza, Keskin Dilek
Department of Biomedical Engineering, Middle East Technical University, Ankara, 06800, Turkey.
J Pharm Sci. 2014 Aug;103(8):2396-405. doi: 10.1002/jps.24058. Epub 2014 Jun 17.
In this study, injectable microspheres were developed for the local treatment of joint degeneration in rheumatoid arthritis (RA). Microspheres loaded with triamcinolone (TA), a corticosteroid drug, and/or raloxifene (Ral), a cartilage regenerative drug, were prepared with a biodegradable and biocompatible polymer, polycaprolactone (PCL). Microspheres were optimized for particle size, structural properties, drug release, and loading properties. In vitro release of Ral was very slow because of the low solubility of the drug and hydrophobic nature of PCL. However, when coloaded with TA, both drugs were released at higher amounts compared with their single forms. Smallest particle sizes were obtained in dual drug-loaded microspheres. In vitro cytotoxicity tests showed biocompatibility of microspheres. In vivo bioefficacy of these microspheres was also examined in adjuvant-induced arthritis model in rats. In vivo histological studies of control groups showed development of RA with high median lesion score (5.0). Compared with control and intra-articular free drug injections, microsphere treatment groups showed lower lesion scores and better healing outcomes in histological evaluations. Results suggest that a controlled delivery system of TA and RAL by a single injection in inflamed joints holds promise for healing and suppressing inflammation.
在本研究中,研发了可注射微球用于类风湿性关节炎(RA)关节退变的局部治疗。用可生物降解且生物相容的聚合物聚己内酯(PCL)制备了负载皮质类固醇药物曲安奈德(TA)和/或软骨再生药物雷洛昔芬(Ral)的微球。对微球的粒径、结构性质、药物释放和负载性质进行了优化。由于雷洛昔芬药物溶解度低以及聚己内酯的疏水性,其体外释放非常缓慢。然而,当与曲安奈德共负载时,两种药物的释放量均高于其单一形式。在双药负载微球中获得了最小的粒径。体外细胞毒性试验表明微球具有生物相容性。还在佐剂诱导的大鼠关节炎模型中研究了这些微球的体内生物疗效。对照组的体内组织学研究显示类风湿性关节炎的发展,中位病变评分较高(5.0)。与对照组和关节内游离药物注射相比,微球治疗组在组织学评估中显示出较低的病变评分和更好的愈合结果。结果表明,在炎症关节中单次注射曲安奈德和雷洛昔芬的控释系统有望实现愈合和抑制炎症。